Literature DB >> 14598072

Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease.

F di Michele1, P Longone, E Romeo, S Lucchetti, L Brusa, M Pierantozzi, A Bassi, G Bernardi, P Stanzione.   

Abstract

The levels of the neuroactive steroids allopregnanolone (THP) and 5alpha-dihydroprogesterone (DHP) were quantified in the plasma of 11 (group 1) and in the liquor of 12 (group 2) Parkinson's disease (PD) patients using a gas-chromatographic/mass-spectrometric method. When compared with controls, both groups showed a significant decrease in DHP and THP concentrations. These decreases could be a useful marker of PD. Moreover, in view of the importance of GABA-ergic transmission to substantia nigra (SN) neurons and GABA-ergic modulation exerted by the two neuroactive steroids, our data indicate a global dysregulation of the SN GABA-ergic system in PD patients. Moreover, a lack of neuroprotective factors (i. e., GDNF, BDNF), promoted by DHP, may contribute to dopaminergic cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598072     DOI: 10.1007/s10072-003-0115-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  17 in total

1.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

2.  Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.

Authors:  Roberto Cosimo Melcangi; Donatella Caruso; Giovanna Levandis; Federico Abbiati; Marie-Therese Armentero; Fabio Blandini
Journal:  J Mol Neurosci       Date:  2011-06-14       Impact factor: 3.444

Review 3.  Neurosteroids and GABAergic signaling in health and disease.

Authors:  Georgina MacKenzie; Jamie Maguire
Journal:  Biomol Concepts       Date:  2013-02

4.  Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Authors:  Carl G Gottschalk; Malabendu Jana; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.167

Review 5.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

6.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

7.  Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Authors:  Mélanie Bourque; Dean E Dluzen; Thérèse Di Paolo
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-30       Impact factor: 5.555

8.  Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

Authors:  Simon McArthur; Glenda E Gillies
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-30       Impact factor: 5.555

Review 9.  Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.

Authors:  Ronald W Irwin; Christine M Solinsky; Roberta Diaz Brinton
Journal:  Front Cell Neurosci       Date:  2014-07-30       Impact factor: 5.505

10.  Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease.

Authors:  Samuel O Adeosun; Xu Hou; Yun Jiao; Baoying Zheng; Sherry Henry; Rosanne Hill; Zhi He; Amar Pani; Patrick Kyle; Xiaoming Ou; Thomas Mosley; Jerry M Farley; Craig Stockmeier; Ian Paul; Steven Bigler; Roberta Diaz Brinton; Richard Smeyne; Jun Ming Wang
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.